Historical Valuation
Mirum Pharmaceuticals Inc (MIRM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.96 is considered Undervalued compared with the five-year average of -18.58. The fair price of Mirum Pharmaceuticals Inc (MIRM) is between 649.56 to 701.56 according to relative valuation methord. Compared to the current price of 80.36 USD , Mirum Pharmaceuticals Inc is Undervalued By 87.63%.
Relative Value
Fair Zone
649.56-701.56
Current Price：80.36
87.63%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Mirum Pharmaceuticals Inc (MIRM) has a current Price-to-Book (P/B) ratio of 13.72. Compared to its 3-year average P/B ratio of 8.64 , the current P/B ratio is approximately 58.73% higher. Relative to its 5-year average P/B ratio of 7.41, the current P/B ratio is about 85.23% higher. Mirum Pharmaceuticals Inc (MIRM) has a Forward Free Cash Flow (FCF) yield of approximately 1.10%. Compared to its 3-year average FCF yield of -4.01%, the current FCF yield is approximately -127.53% lower. Relative to its 5-year average FCF yield of -10.51% , the current FCF yield is about -110.51% lower.
P/B
Median3y
8.64
Median5y
7.41
FCF Yield
Median3y
-4.01
Median5y
-10.51
Competitors Valuation Multiple
AI Analysis for MIRM
The average P/S ratio for MIRM competitors is 231.52, providing a benchmark for relative valuation. Mirum Pharmaceuticals Inc Corp (MIRM.O) exhibits a P/S ratio of 6.96, which is -97% above the industry average. Given its robust revenue growth of 47.17%, this premium appears sustainable.
Performance Decomposition
AI Analysis for MIRM
1Y
3Y
5Y
Market capitalization of MIRM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MIRM in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MIRM currently overvalued or undervalued?
Mirum Pharmaceuticals Inc (MIRM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.96 is considered Undervalued compared with the five-year average of -18.58. The fair price of Mirum Pharmaceuticals Inc (MIRM) is between 649.56 to 701.56 according to relative valuation methord. Compared to the current price of 80.36 USD , Mirum Pharmaceuticals Inc is Undervalued By 87.63% .
What is Mirum Pharmaceuticals Inc (MIRM) fair value?
MIRM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Mirum Pharmaceuticals Inc (MIRM) is between 649.56 to 701.56 according to relative valuation methord.
How does MIRM's valuation metrics compare to the industry average?
The average P/S ratio for MIRM's competitors is 231.52, providing a benchmark for relative valuation. Mirum Pharmaceuticals Inc Corp (MIRM) exhibits a P/S ratio of 6.96, which is -97.00% above the industry average. Given its robust revenue growth of 47.17%, this premium appears sustainable.
What is the current P/B ratio for Mirum Pharmaceuticals Inc (MIRM) as of Jan 09 2026?
As of Jan 09 2026, Mirum Pharmaceuticals Inc (MIRM) has a P/B ratio of 13.72. This indicates that the market values MIRM at 13.72 times its book value.
What is the current FCF Yield for Mirum Pharmaceuticals Inc (MIRM) as of Jan 09 2026?
As of Jan 09 2026, Mirum Pharmaceuticals Inc (MIRM) has a FCF Yield of 1.10%. This means that for every dollar of Mirum Pharmaceuticals Inc’s market capitalization, the company generates 1.10 cents in free cash flow.
What is the current Forward P/E ratio for Mirum Pharmaceuticals Inc (MIRM) as of Jan 09 2026?
As of Jan 09 2026, Mirum Pharmaceuticals Inc (MIRM) has a Forward P/E ratio of -306.16. This means the market is willing to pay $-306.16 for every dollar of Mirum Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Mirum Pharmaceuticals Inc (MIRM) as of Jan 09 2026?
As of Jan 09 2026, Mirum Pharmaceuticals Inc (MIRM) has a Forward P/S ratio of 6.96. This means the market is valuing MIRM at $6.96 for every dollar of expected revenue over the next 12 months.